Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
PMID: 39561272Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2024 Dec 09; 10781552241305417.
PMID: 39648753High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2024 Nov 23.
PMID: 39579248Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers.
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers. Clin Cancer Res. 2024 Nov 19.
PMID: 39561272Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
PMID: 39510069Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer.
Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer. Sci Adv. 2024 Oct 25; 10(43):eadp2622.
PMID: 39441940Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer. J Oncol Pharm Pract. 2024 Oct 13; 10781552241289581.
PMID: 39397422Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2024 Sep 21.
PMID: 39305392Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
PMID: 39277672Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
View All Publications
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
PMID: 39277671
Our Faculty
Rita Nanda, MD
- Associate Professor of Medicine
- Clinical Interests: Breast Cancer
- Websites: Research Network Profile
- Contact: rnanda@uchicago.edu
- Graduate Program: UChicago Biosciences